Table 1 Baseline demographics grouped according to the access closure strategy on ICU.

From: Manual compression versus MANTA device for access management after impella removal on the ICU

 

Overall (n = 87)

MANTA device (n = 31)

Manual compression (n = 56)

P value*

Age (years)

66.1 ± 10.7

64.7 ± 9.1

66.9 ± 11.5

0.37

Female (%)

21 (24.1)

6 (19.4)

15 (26.8)

0.44

BMI (kg/m2)

26.1 ± 4.0

26.3 ± 4.6

26.0 ± 3.7

0.74

Cardiac arrest prior to admission

45 (51.7)

12 (38.7)

33 (58.9)

0.07

Cause of CS

   

0.53

STEMI

51 (58.6)

16 (51.6)

35 (62.5)

 

NSTEMI/unstable AP

21 (24.1)

8 (25.8)

13 (23.2)

 

No ACS

15 (17.2)

7 (22.6)

8 (14.3)

 

Comorbidities

Previous PCI

17 (19.5)

9 (29.0)

8 (14.3)

0.09

Previous MI

14 (16.1)

6 (19.4)

8 (14.3)

0.54

Previous CABG

8 (9.2)

2 (6.5)

6 (10.7)

0.51

PAD

12 (13.8)

6 (19.4)

6 (10.7)

0.26

Previous stroke/TIA

6 (6.9)

4 (12.9)

2 (3.6)

0.10

History of heart failure

3 (3.4)

0 (0)

3 (5.4)

0.19

Diabetes

27 (31.0)

14 (45.2)

13 (23.2)

0.039

Arterial hypertension

49 (56.3)

19 (61.3)

30 (53.6)

0.48

Dyslipidemia

36 (41.4)

14 (45.2)

22 (39.3)

0.59

Obesity (BMI > 30)

15 (17.2)

8 (25.8)

7 (12.5)

0.20

Current smoking

18 (20.7)

9 (29)

9 (16.1)

0.15

Chronic kidney disease†

11 (12.6)

4 (12.9)

7 (12.5)

0.95

Preexisting anemia

4 (4.6)

2 (6.5)

2 (3.6)

0.61

Initial LVEF

25 ± 8

25 ± 6

25 ± 9

0.77

LVEDP (mmHg)

32 ± 9

34 ± 9

32 ± 8

0.46

Laboratory parameters‡

Peak lactate (mmol/L)

2.6 (1.7–4.5)

2.4 (1.6–3.2)

2.7 (1.9–5)

0.11

eGFR (CKD-EPI) (ml/min/1.73m2)

72 (52–91)

74.5 (63.5–91)

67 (48–90)

0.16

Peak troponin T (ng/L)

4323 (1547–12,384)

2901 (1547–9630)

4907 (1519–15,481)

0.29

Peak CK (IU/L)

3002 (811–6078)

1754 (779–5027)

3445 (992–6531)

0.29

Hemoglobin prior to closure (g/L)

97.8 ± 18.8

105 ± 20.1

93.8 ± 16.9

0.007

Thrombocytes (G/L)

160 ± 89

188 ± 104

145 ± 77

0.036

Anti-Xa level (U/mL)

0.47 (0.23–0.83)

0.54 (0.21–0.89)

0.47 (0.23–0.80)

0.73

Type of intervention performed

PCI performed

75 (86.2)

26 (83.9)

49 (87.5)

0.64

CABG performed

3 (3.4)

2 (6.5)

1 (1.8)

0.25

Antithrombotics§

Aspirin

78 (89.7)

26 (83.9)

52 (92.9)

0.19

Ticagrelor

56 (64.4)

17 (54.8)

39 (69.6)

0.16

Cangrelor

9 (10.3)

7 (22.6)

2 (3.6)

0.006

Prasugrel

1 (1.1)

0 (0)

1 (1.8)

0.45

Clopidogrel

9 (10.3)

3 (9.7)

6 (10.7)

0.87

GPIIbIIIa inhibitors

9 (10.3)

1 (3.2)

8 (14.3)

0.10

Unfractionated heparin

67 (77.0)

28 (90.3)

39 (69.6)

0.029

DOACs

2 (2.3)

0 (0)

2 (3.6)

0.28

  1. Data are median (interquartile range) or number (percentage), as appropriate. AP, angina pectoris; BMI, body mass index; CS, cardiogenic shock; STEMI, ST-segment–elevation acute myocardial infarction; NSTEMI, non–ST-segment–elevation myocardial infarction; PCI, percutaneous coronary intervention; MI, myocardial infarction; PAD, peripheral arterial disease; CABG, coronary artery bypass grafting; TIA, transient ischemic attack; Hb, hemoglobin; LVEF, left ventricular ejection fraction; LVEDP, left ventricular end diastolic pressure; eGFR (CKD-EPI), estimated glomerular filtration rate (Chronic Kidney Disease Epidemiology Collaboration); CK, creatine kinase; DOAC, direct oral anticoagulant agents.
  2. *P values were based on Fisher's exact, Man-Whitney-U test or student's t-test, as appropriate.
  3. †Chronic kidney disease was defined as a preexisting eGFR < 45 ml/min/m2.
  4. ‡Values of laboratory parameters prior to access closure are represented (either first or peak, as appropriate).
  5. §This comprised antithrombotics, which had been administered after Impella implantation and/or prior to device removal.
Back to article page